Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- máculas ou placas escamosas, únicas ou múltiplas
- lesões escamosas com uma superfície hiperceratótica
- lesões marrons, escamosas, bem-definidas
- lesões semelhantes a ceratoses seborreicas, nevos melanocíticos e melanoma maligno precoce
- protuberâncias hipertróficas, em forma cônica, que crescem a partir da superfície da pele
- aspereza avermelhada escamosa com induração, fissuras e ulceração do lábio inferior e borda vermelha
- lesão sobre área corporal exposta ao sol
- pápulas tipo verruga elevada, papilomatosas, cor da pele
- placas com escamas bem leves sobre pele brilhante muito fina
- pápulas bem-definidas, violáceas, com linhas brancas finas na superfície
Fatores de risco
- exposição crônica à radiação UVB
- cor de pele clara, sardas e albinismo
- idade >40 anos
- sexo masculino
- imunocomprometimento
- xeroderma pigmentoso
Investigações diagnósticas
Algoritmo de tratamento
Colaboradores
Autores
Brian Berman, MD, PhD
Professor Emeritus of Dermatology and Cutaneous Surgery
University of Miami Miller School of Medicine
Miami
Skin & Cancer Associates, LLP
Co-Director
Center for Clinical and Cosmetic Research
Aventura
FL
Declarações
BB is, or has been, a paid consultant/advisor for Almirall (manufacturer of tirbanibulin), Lemonex, Berg/BPGBio Pharma, Novartis, Aiviva, Ferndale, Sensus, Novan, Pierre Fabre (manufacturer of 5-FU), Biofrontera (manufacturer of ALA), SUN (manufacturer of ALA), LEO (manufacturer of ingenol mebutate - removed from market), Sirnaomics, Menlo, Sonoma, PHD Biosciences, Birch BioMed, Mediwound, Mino Labs, and Thirona. He has been a speaker for Almirall (manufacturer of tirbanibulin), LEO (manufacturer of ingenol mebutate), and Sensus. His institution has received investigator funding from Biofrontera (manufacturer of ALA), LEO (manufacturer of ingenol mebutate), Pulse, Sirnaomics, Menlo, Birch BioMed, and Mediwound. BB has stock options in Thirona and Mino Labs.
Sadegh Amini, MD
Dermatologist
Skin and Cancer Associates
Voluntary Assistant Professor
Department of Dermatology and Cutaneous Surgery
University of Miami
Miller School of Medicine
Miami
FL
Declarações
SA has been compensated by Primus Pharmaceuticals, Inc. for being a member of the clinical advisory board.
Revisores
David S. Cassarino, MD, PhD
Assistant Professor
Departments of Pathology and Dermatology
UCLA
Los Angeles
CA
Declarações
DSC declares that he has no competing interests.
Christopher Shea, MD
Dermatopathology Fellowship Director
University of Chicago
Section of Dermatology
Chicago
IL
Declarações
CS declares that he has no competing interests.
Referências
Principais artigos
Berman B, Bienstock L, Kuritzky L, et al. Primary Care Education Consortium; Texas Academy of Family Physicians. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract. 2006 May;55(5):suppl 1-8. Resumo
de Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017 Jan;176(1):20-43. Resumo
Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021 Oct;85(4):e209-33.Texto completo Resumo
European Dermatology Forum. Evidence and consensus based (S3) guidelines for the treatment of actinic keratosis. 2015 [internet publication].Texto completo
Eisen DB, Dellavalle RP, Frazer-Green L, et al. Focused update: guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2022 Aug;87(2):373-4.e5.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível aqui.
O uso deste conteúdo está sujeito ao nosso aviso legal